O’Melveny’s Deaton Quoted in Scrip Intelligence on Self-Reporting FCPA Violations

August 09, 2012

O’Melveny & Myers LLP Los Angeles partner David Deaton was quoted in the August 9, 2012, Scrip Intelligence article “Self-reporting limits Pfizer’s corrupt practices penalties as US widens industry net.” The article reported on the trend of pharmaceutical companies increasingly self-reporting their violations of the Foreign Corrupt Practices Act (FCPA) in order to lessen penalties.


In the article, Deaton, co-chair of O’Melveny’s Health Care and Life Sciences Practice and a member of the Firm’s White Collar Defense and Corporate Investigations Practice, said “Pfizer self-disclosed, took aggressive remedial actions, adopted strong compliance measures and the government gave them credit for that. The way Pfizer handled this should serve as something of a blueprint for others who are thinking of how to resolve an FCPA issue. The best way to do this is to take the strong medicine yourself and show them how strong and proactive you have been.”